Earnings Releases·Nov 10, 2026, 4:10 PM ET

Atara Biotherapeutics — Third Quarter 2026 Earnings Summary

Q3 2026 revenue declined 66% year-over-year to $1.2 million due to a prior-year one-time inventory sale, while net loss narrowed to $2.2 million ($0.15/share) from $4.3 million ($0.32/share) in Q3 2025; operating expenses fell 40% to $4.2 million and cash burn reduced to $0.9 million.
The FDA established a Class 2 PDUFA target action date of March 31, 2027, for the tab-cel BLA resubmission, with approval expected to unlock a $31 million milestone payment and future tiered royalties.
Management projects operating expenses will continue to decline significantly in 2026, and current cash resources of $9.9 million are sufficient to fund operations into mid-2027.
Total liabilities decreased to $56.5 million from $58.7 million in December 2025, though the liability related to the sale of future revenues increased to $40.7 million.
Pierre Fabre retains control of the BLA content and FDA strategy, presenting a risk that the resubmission may not address prior deficiencies or that Atara may face challenges accessing capital.